Participant characteristics (N=192)
| Median (IQR) for continuous variables, % (n) for proportions | |
| Clinical | |
| Female, n (%) | 58.3 (112/192) |
| Age, years | 56 (50–63) |
| Duration of diabetes, years | 6 (3–10) |
| BMI, kg/m2 | 26.8 (24.0–30.5) |
| Current management, n (%) | |
| Metformin only | 15.6 (30/192) |
| SU (±metformin)* | 57.3 (110/192) |
| Insulin (±other diabetes drug)† | 26.0 (50/192) |
| Diet‡ | 1.0 (2/192) |
| Glycemia | |
| CGM glucose, mmol/L | 8.6 (6.8–12.3) |
| HbA1c, % | 8.3 (6.9–10.0) |
| HbA1c, mmol/mol | 67 (52.0–90.0) |
| FPG, mmol/L | 8.2 (6.1–11.4) |
| RPG, mmol/L | 13.5 (8.8–17.2) |
| Other laboratory | |
| Hb (g/L) | 14.2 (13.2–15.0) |
| Anemia§ | 9.4% (18/192) |
| Hemoglobinopathies, n (%)¶ | 22.4% (43/192) |
| eGFR | 111.5 (92.3–121.0) |
| Renal impairment, n (%) | 6.3% (12/192) |
*Sulfonylureas with or without metformin.
†Insulin with or without any oral therapy.
‡Two participants were on non-pharmacological management (diet) only.
§ Anemia was defined as a Hb of <120 g/L in women and <130 g/L in men.
¶Hemoglobinopathies was defined as the presence of sickle cell trait (HbAS) or HbAC.
BMI, body mass index; CGM, continuous glucose monitoring; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; Hb, hemoglobin; HbAC, hemoglobin AC; HbA1c, glycosylated hemoglobin; RPG, random non-fasting plasma glucose.